NATCO launches generic Pomalidomide Capsules in Canada
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
Clinical studies are expected to start in Q2 2023.
Subscribe To Our Newsletter & Stay Updated